Moderna, Inc.
MRNAHealthcareNASDAQBiotechnology · Last scanned Jun 2, 2026
Scan Results
Daily timeframeModerna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company carries a $18.28B market cap, placing it firmly in the large-cap category. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Market Cap
$18.28B
Beta
1.06
P/E (TTM)
—
P/E (Fwd)
-10.96
EPS (TTM)
$-8.14
EPS (Fwd)
$-4.20
ROE
-36.6%
ROA
-13.1%
Cash
$5.21B
Total Debt
$1.30B
Free CF
-$20.0M
52W Change
65.6%
Annual Financials
Cash vs Debt
Moderna, Inc. holds $5.21B in cash against $1.30B in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$20.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -36.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $18.88B (2022) to $1.92B (2025), a 90% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MRNA.